FindTrial
Sign In

Benefits and risks for connective tissue disease associated interstitial lung disease (CTD-ILD)

A single-center retrospective study on the assessment of therapeutic benefits and risks for connective tissue disease associated interstitial lung disease (CTD-ILD) and interstitial pneumonia with autoimmune features (IPAF)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112369
Enrollment
Unknown
Registered
2025-11-13
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Connective tissue disease-associated interstitial lung disease, including systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), rheumatoid arthritis (RA), Sjögren's syndrome (SS), mixed connective tissue disease (MCTD), vasculitis-associated ILD

Interventions

low-dose glucocorticoid group:None
Untreated group:None
Low-dose glucocorticoids + immunosuppressants:None
Low-dose glucocorticoids + immunosuppressants + cyclophosphamide group:None

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.diagnosed CTD-ILD/IPAF; 2.Standardized treatment >= 6 months, complete clinical data; 3.Exemptions from informed consent; 4.Age >= 18 years;

Exclusion criteria

Exclusion criteria: 1.lung transplantation, lung surgery before standardized treatment; 2.Combined lung cancer, severe cardiovascular disease;

Design outcomes

Primary

MeasureTime frame
FVC% difference with baseline;—

Secondary

MeasureTime frame
DLCO% difference with baseline;Difference between HRCT score and baseline;—

Countries

China

Contacts

Public ContactLi Feng

Shanghai Chest Hospital

lifeng741@aliyun.com+86 21 2220 0000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026